Background Juvenile polyposis syndrome is an inherited condition associated with the development of gastrointestinal polyps and subsequent cancer. An efficient denaturing high-performance liquid chromatography (DHPLC) screening method has been developed to detect mutations in SMAD4, which account for around 20% of reported cases.
Introduction
Juvenile polyposis syndrome (OMIM 174900) is an autosomal dominant disorder with an incidence of 1/100,000 that predisposes a¡ected individuals to the development of hamartomatous gastrointestinal polyps. A¡ected individuals have a high risk (greater than 50%) of developing gastrointestinal malignancy, as juvenile polyps can become cancerous by epithelial dysplasia. 1, 2 Most patients show clinical signs of disease within the ¢rst two decades of life. The primary manifestation of juvenile polyposis syndrome is colorectal bleeding, which can result in iron-de¢cient anaemia. 3 Adults commonly present with between 50 and 200 polyps, which can occur throughout the gastrointestinal tract and continue to be formed during the individual's lifetime. The mean age for the development of colorectal cancer is 34 years, and this is associated with a poor clinical outcome.
The transforming growth factor-b (TGF-b) signalling pathway is highly implicated in the pathogenesis of juvenile polyposis syndrome. Cytoplasmic SMA-and MAD-related (SMAD) proteins are phosphorylated by type I receptors, whereupon they form hetero-oligomeric complexes with the common mediator, SMAD4. These complexes inhibit cell growth by a¡ecting the transcription of target genes in the nucleus. A breakdown in this pathway may cause cells to become resistant to TGF-b and thus escape from growth control and apoptosis. Somatic mutational inactivation of SMAD4 has been implicated in a variety of human cancers, including pancreatic, prostatic and colorectal carcinomas. 4 The SMAD4 gene encompasses 11 exons spanning a total length of 51kbp. More than 30 unique germline mutations in SMAD4 (18q21.1; NM_005359; DPC4, MADH4) have been reported to cause juvenile polyposis syndrome, 5--8 and the prevalence of SMAD4 mutations is estimated at 18.2%. 5 Genes encoding SMADs 1--3, 5 and 7 have not been found to be associated with juvenile polyposis syndrome. 9, 10 Regular endoscopic screening is recommended for the juvenile polyposis syndrome proband and their ¢rst-degree relatives. Occasional polyps are resected, although prophylactic colonectomy or gastrectomy may be recommended if di¡use polyposis is identi¢ed. 3 The ability to safely eliminate non-carriers from the endoscopic screening programme by pre-symptomatic genetic testing is, therefore, highly desirable and would also enable greater attention to be focused on those at risk. Genetic testing is virtually 100% accurate following identi¢cation of the pathogenic mutation, and reliable clinical and histopathological diagnosis could help to direct the search for a pathogenic mutation to the appropriate gene. The ¢nancial costs of genetic screening should be o¡set by signi¢cant reductions in endoscopies.
Denaturing high-performance liquid chromatography (DHPLC) is proposed as an e⁄cient method for screening the SMAD4 gene for both known and unknown mutations; positive screening results would be followed up by directed sequencing of the a¡ected exon. DHPLC has previously been applied to the detection of mutations in BMPR1A, another causative gene in juvenile polyposis syndrome. 11 
Methods

DNA samples
DNA samples from two families who had been referred to the NorthWest Thames Regional Genetics Service for genetic determination of their juvenile polyposis syndrome status were selected for analysis. Two siblings from the ¢rst family were known to share a gross insertion/deletion in exon one of SMAD4, c.189_190delins44, while another sibling had been found to be mutation negative. A single individual from the second family had a known mutation in exon two of SMAD4, c.403C4T (p.Arg135X), while three other family members were mutation negative. Three additional DNA samples from colorectal cancer cell lines containing known somatic mutations in SMAD4, c.715C4T (p.Gln239X), c.1051G4C (p.Asp351His), and c.1619T4G (p.Leu540Arg), were kindly donated by Professor Ian Tomlinson of Cancer Research UK. Multiple wild-type control DNA samples were selected for comparative analysis.
Polymerase chain reaction amplification SMAD4 (ENSG00000141646) was ampli¢ed using polymerase chain reaction (PCR) primers (Invitrogen; Scotland, UK) that have been published previously (Table 1 ). 12 PCRs for DHPLC analysis were performed in WAVEt PCR tubes (Transgenomic; Omaha, USA) in a volume of 100 mL on a Primus 96 Plus (MWG Biotech; Germany). PCR tubes were incubated at 941C for 4 min to completely denature the template. Thirty or 35 cycles of PCR ampli¢cation were performed: denaturation at 941C for 1min, annealing at the optimized PCR tem-perature for 1min and extension at 721C for 1min. A ¢nal extension incubation was performed at 721C for 10 min. Each PCR contained 200 nmol MgCl 2 , 20 nmol dNTPs, 67 pmol forward and reverse primers, 8.3 mg genomic DNA and 3.5 U Taq polymerase (Invitrogen; Scotland, UK) in 1 Â PCR bu¡er.
DNA melt analysis
WAVEMAKERt software (Transgenomic; Omaha, USA) contains an algorithm that performs predictive DNA melt analysis. The nucleotide sequence of each SMAD4 fragment was examined usingWAVEMAKERt in order to calculate the theoretical melting temperature (T m ), and to generate melting curves of helical fraction versus temperature and melting pro¢les of temperature versus base position. The melt pro¢les show the extent of denaturation at a range of partially denaturing oven temperatures. A series of temperatures was then selected for each fragment to give progression from partially unwound fragment ends to full denaturation along its length.
Denaturing HPLC
PCR products were denatured prior to DHPLC analysis using a PCR programme of brief heating to 951C for 5 min followed by slow cooling to 261C at a rate of 11C every 22 s. The volume of PCR product used for each DHPLC analysis was varied between 8 and12 mL, determined by visual inspection of the brightness of the DNA band under UV following agarose electrophoresis. The HPLC column was a pre-heated reverse-phase DNAsep column, and elution was performed with an acetonitrile gradient (Transgenomic; Omaha, USA).
Wild-type DHPLC elution pro¢les were characterized for each exon fragment by analysing 10 control DNA samples at every column oven temperature selected. The ability to detect heteroduplexes was veri¢ed by comparison of wild-type DHPLC pro¢les with those of known sequence variants wherever possible. The DNA obtained from colorectal cancer cell lines did not contain any wild-type copies of SMAD4; therefore, wildtype PCR products were mixed with these PCR products in a 1:1 ratio prior to denaturation to permit the formation of heteroduplexes.
Results
Method optimization
DHPLC analysis of wild-type samples produced a single peak for each exon throughout the range of column oven temperatures, with the exceptions outlined below, suggesting an absence of polymorphisms that will facilitate the identi¢cation of mutations. Two di¡erent and distinctive pro¢les were observed for wild-type samples at a relative frequency of 1:1 for exon 2 at 52--541C, multiple peaks were observed for the exon 5/6 fragment at 52--541C and two peaks of varying proportions at 551C, and a pronounced leftsided shoulder was present for exon 11 at 56--581C. It was postulated that these unexpected patterns were due to the presence of polymorphisms, most likely located within the intronic sequences of each fragment. Sequencing of exon 5/6 revealed a high level of sequence variation in intron 7, downstream from c.904 þ 45. Thus, the unusual DHPLC pro¢les observed for this exon are attributed to a long and highly variable polymorphic sequence within intron 7. Similarly, sequencing of exon 2 revealed two polymorphic substitutions in intron 3: c.424 þ33T4A and c.424 þ 86T4A.
The DHPLC pro¢le of exon 1 for the patient with c.189_190delins44 was distinguishable by the presence of three very clear and separate peaks at 53--571C (Figure 1a ), compared with a single peak for the wildtype control sample and other patients. A third sibling was una¡ected across all exons.
The DHPLC pro¢le of exon 2 for the con¢rmed juvenile polyposis syndrome patient (c.403C4T, R135X) was distinguishable from the control samples and una¡ected siblings at 56--601C. This was particularly marked at 57--591C, and is consistent with the observation that the locus for this mutation ¢rst melts at 561C (Figure 1b) .
Examination of the melt pro¢le predicted detection of c.715C4T (p.Gln239X) at 591C; in practice, this was distinguished by a subsidiary left-sided peak at 591C (Figure 1c ). c.1051G4C (p.Asp351His) was predicted to be detected at 58--591C; this could be distinguished from the control samples as an emerging left-sided shoulder at 54--551C and a pronounced left-sided shoulder at 56--571C (Figure 1d ). c.1619T4G (p.Leu540Arg) was predicted from the melt pro¢le to be detected at 59--601C and was reliably distinguished as a left-sided shoulder at 59.51C, more pronounced at 60--611C (Figure 1e ).
Patient analysis
Four previously untested putative juvenile polyposis syndrome index cases were screened across all exons for SMAD4 mutations. However, no SMAD4 mutations were identi¢ed in these patients, or in ¢ve further cases with gastrointestinal polyps previously referred due to suspected PTEN hamartoma-tumour syndrome but who were PTEN mutation negative.
Discussion
This method has been shown to reliably detect a variety of mutations, including a large insertion/deletion and a number of single point substitutions. Five mutations were successfully detected: c.189_190delins44 (exon 1), c.403C4T (exon 2), c.715C4T (exon 5), c.1051G4C (exon 8) and c.1619T4G (exon 11). The DHPLC method exhibited a high degree of rationale, as the temperatures at which known mutations were detected could generally be predicted from the melting pro¢les according to the base position: optimal detection of mutations has previously been reported at a helical fraction of 70--851C. 13 In order to maximize the practicality of the DHPLC screening approach for routine mutation detection in SMAD4 it was necessary to select a small number of column oven temperatures from the range investigated to give an optimized screening protocol (Table 1) . Since a mutation could occur in any position within the coding sequence or intronic splice sites, it was necessary to choose temperatures that gave rise to melting domains that collectively encompassed all exonic sequences plus the £anking splice sites. Suitable temperatures were identi¢ed by reference to melt pro¢les of helical fraction versus base position. The clarity of elution pro-¢les observed at each temperature was also considered, gauged via the width and height of homoduplex peaks: clearly de¢ned wild-type pro¢les are essential for reliable mutation detection. Generally, the lowest possible temperatures were selected in order to minimize peak broadening, which was observed to increase with column oven temperature for all fragments of SMAD4.
The PCR primers used in this method were used by Howe et al. for direct sequencing, and they included some intronic material within each amplicon. These could be considered advantageous, as it o¡ers the potential to detect deleterious mutations in splice sites or the promoter region. However, it has become apparent that introns can complicate the interpretation of DHPLC pro¢les due to the high level of sequence variation in non-coding regions. This problem is illustrated by the exon 2 and 5/6 fragments, both of which contain polymorphic intronic substitutions, as revealed by sequencing, and produced multiple peaks across a range of DHPLC temperatures. A second problem with the inclusion of introns was the e¡ect this has on the melting pro¢le of each fragment: introns melt at lower temperature than exons, as exempli¢ed by the exon 5/6 fragment; further method optimization is required to allow these exons to be analysed as separate amplicons. Thus, screening of introns would necessitate the inclusion of lower temperatures, expanding the screening protocol. It is therefore advisable to minimize the length of intronic material included in DHPLC analysis: this should ideally be restricted to include only sequences necessary for correct splicing. This screening protocol for SMAD4 requires 35 DHPLC analyses. It is possible to further improve the e⁄ciency and cost-e¡ectiveness of screening juvenile polyposis syndrome index cases by prioritizing exons according to the frequency with which mutations have previously been observed. In such a scheme, the ¢rst exons to be screened should be exons 8, 9 (the site of a mutational hotspot), 10 and 11, in which a total of 18 mutations have been documented. The remaining exons (1--7) would only be screened subsequently in the absence of positive mutation detection in exons 8--11, as only six mutations have been documented in that region.
Conclusion
A sensitive and speci¢c DHPLC method for screening for SMAD4 mutations has been developed. This method is applicable to the identi¢cation of unknown mutations in patients with suspected juvenile polyposis syndrome and the screening of family members of patients with con¢rmed SMAD4 mutations that have been previously characterized. New mutations should be subsequently characterized by sequencing the speci¢c exon concerned. Una¡ected individuals can be safely eliminated from colorectal screening.
